Open AccessStructural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer’s Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years
Author(s) -
Arunima Kapoor,
Robert Bartha,
Sandra E. Black,
Michael Borrie,
Morris Freedman,
Fuqiang Gao,
Nathan Herrmann,
Jennifer Mandzia,
Miracle Ozzoude,
Joel Ramirez,
Christopher J. Scott,
Sean Symons,
Corinne E. Fischer,
Andrew Frank,
Dallas Seitz,
Michael Wolf,
Nicolaas Paul L.G. Verhoeff,
Gary Naglie,
William E. Reichman,
Mario Masellis,
Sara Mitchell,
David F. TangWai,
Maria Carmela Tartaglia,
Sanjeev Kumar,
Bruce G. Pollock,
Tarek K. Rajji,
Elizabeth Finger,
Stephen Pasternak,
Ondri Investigators,
Richard H. Swartz
Publication year - 2020
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-191097
Subject(s) - medicine , clinical trial , magnetic resonance imaging , neuroimaging , dementia , alzheimer's disease neuroimaging initiative , cohort , disease , cohort study , pathology , radiology , psychiatry
Structural brain magnetic resonance imaging (MRI) is not mandatory in Alzheimer's disease (AD) research or clinical guidelines. We aimed to explore the use of structural brain MRI in AD/mild cognitive impairment (MCI) trials over the past 10 years and determine the frequency with which inclusion of standardized structural MRI acquisitions detects comorbid vascular and non-vascular pathologies.